On the Record · Edwards Lifesciences
Edwards Lifesciences acquisitions, on the record
The businesses Edwards Lifesciences bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
medical technology companyWord for word“On February 28, 2023, we acquired a majority equity interest in a medical technology company.” 10-K for 2023 | agreed acquisition | On February 28, 2023 | — |
medical device companyWord for word“In March 2023, the Company agreed to pay a medical device company up to $ 45.0 million as consideration for an option to acquire the medical device company, of which $ 30.0 million had been paid as of December 31, 2023.” 10-K for 2023 | agreed acquisition | March 2023 | up to $ 45.0 million |
Critical Care product groupWord for word“On September 3, 2024, we sold our Critical Care product group to Becton, Dickinson and Company.” 10-K for 2024 | divestiture | On September 3, 2024 | — |
Endotronix, Inc.Word for word“we completed the acquisition of Endotronix, Inc., a leader in heart failure management solutions;” 10-K for 2024 | acquisition | we completed the acquisition of Endotronix, Inc., a leader in heart failure management solutions | — |
Innovalve Bio Medical Ltd.Word for word“we completed the acquisition of Innovalve Bio Medical Ltd., an early-stage transcatheter mitral replacement company; and” 10-K for 2024 | acquisition | we completed the acquisition of Innovalve Bio Medical Ltd., an early-stage transcatheter mitral replacement company | — |
JC Medical, Inc.Word for word“we completed the acquisition of JC Medical, Inc., an early-stage company developing a TAVR technology for patients with aortic regurgitation.” 10-K for 2024 | acquisition | we completed the acquisition of JC Medical, Inc., an early-stage company developing a TAVR technology for patients with aortic regurgitation | — |
multiple medical device companiesWord for word“In July 2024, we entered into agreements and plans of mergers to acquire multiple medical device companies for a total aggregate cash purchase price of $1.5 billion, subject to certain adjustments.” 10-K for 2024 | agreed acquisition | In July 2024, we entered into agreements and plans of mergers to acquire multiple medical device companies | $1.5 billion |
JenaValve Technology, Inc.Word for word“In July 2024, the Company entered into an agreement and plan of merger to acquire JenaValve Technology, Inc. ("JenaValve").” 10-K for 2024 | agreed acquisition | In July 2024 | — |
non-core product groupWord for word“On December 18, 2025, the Company completed the sale of its non-core product group for $ 81.8 million up-front consideration (net cash proceeds of $ 78.8 million), resulting in a gain of $ 36.9 million (included in Income from Discontinued Operations, net of tax) .” 10-K for 2025 | divestiture | December 18, 2025 | $ 81.8 million up-front consideration |
remaining noncontrolling interest of Vectorious Medical TechnologiesWord for word“During the year ended December 31, 2025, the Company acquired the remaining noncontrolling interest of Vectorious for $ 233.7 million, increasing the Company's total ownership from 61 % to 100 %.” 10-K for 2025 | acquisition | During the year ended December 31, 2025 | $ 233.7 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $0 | — | $0 |
| 2017-12-31 | $192.9 million | — | $458.6 million |
| 2018-12-31 | $0 | — | — |
| 2019-12-31 | $100.2 million | — | $64.4 million |
| 2022-12-31 | — | $0 | — |
| 2023-12-31 | — | $0 | $78.4 million |
| 2024-12-31 | — | $0 | $634.6 million |
| 2025-12-31 | — | $78.8 million | — |
Deal filings since 2016
- 2022-07-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-06-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-04-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-23 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
Read from Edwards Lifesciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.